New drug targets tough lung cancer mutation in small trial
NCT ID NCT03808558
First seen Jan 11, 2026 · Last updated Jun 03, 2026 · Updated 18 times
Summary
This study tests an experimental drug called TVB-2640 in 18 adults with a specific type of advanced lung cancer (KRAS-mutant NSCLC) that has not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing over 8 weeks. Researchers will also check safety and use special scans to understand how the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390-9179, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.